Blueprint Medicines
BPMC
$107.55
Share price
1.98%
Change (1 day)
95.05%
Change (1 year)
Categories
P/S ratio for Blueprint Medicines (BPMC)
P/S ratio as of May 2024 (TTM): 26.5
According to Blueprint Medicines 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 26.48. At the end of 2023 the company had a P/S ratio of 22.5.
P/S ratio history for Blueprint Medicines from 2015 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 22.5 | 75.02% |
| 2022 | 12.8 | -63.29% |
| 2021 | 35.0 | 344.43% |
| 2020 | 7.87 | -86.73% |
| 2019 | 59.3 | 11.29% |
| 2018 | 53.3 | -65.14% |
| 2017 | 153 | 357.88% |
| 2016 | 33.4 | -46.58% |
| 2015 | 62.5 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pacific Biosciences
PACB | 3.03 | -88.56% | 🇺🇸 USA |
 OPKO Health
OPK | 1.05 | -96.02% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Isoray
ISR | 11.9 | -54.94% | 🇺🇸 USA |